Avoro Capital Advisors LLC - Q1 2023 holdings

Add to watchlist

$6.75 Billion is the total value of Avoro Capital Advisors LLC's 41 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 31.2% .

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
APLS BuyAPELLIS PHARMACEUTICALS INC$732,888,882
+33.4%
11,111,111
+4.6%
10.86%
+32.3%
UTHR BuyUNITED THERAPEUTICS CORP$642,765,200
-19.3%
2,870,000
+0.2%
9.53%
-20.0%
SRPT BuySAREPTA THERAPEUTICS INC$503,079,500
+22.3%
3,650,000
+15.0%
7.46%
+21.3%
ARGX BuyARGENX SEsponsored adr$479,696,750
+0.1%
1,287,500
+1.7%
7.11%
-0.7%
MDGL BuyMADRIGAL PHARMACEUTICALS INC$403,766,505
-16.2%
1,666,666
+0.4%
5.99%
-16.9%
BMRN BuyBIOMARIN PHARMACEUTICAL INC$383,611,800
+4.3%
3,945,000
+11.0%
5.69%
+3.4%
ASND BuyASCENDIS PHARMAsponsored adr$356,506,500
-5.8%
3,325,000
+7.3%
5.28%
-6.6%
FOLD BuyAMICUS THERAPEUTICS INC$302,757,000
-7.5%
27,300,000
+1.9%
4.49%
-8.2%
ISEE BuyIVERIC BIO INC$165,444,000
+14.5%
6,800,000
+0.7%
2.45%
+13.6%
KRYS BuyKRYSTAL BIOTECH INC$140,105,000
+25.4%
1,750,000
+24.1%
2.08%
+24.4%
KYMR BuyKYMERA THERAPEUTICS INC$114,223,650
+18.9%
3,855,000
+0.1%
1.69%
+17.9%
BuyDICE THERAPEUTICS INC$113,167,500
+43.6%
3,950,000
+56.4%
1.68%
+42.4%
BCRX BuyBIOCRYST PHARMACEUTICALS INC$86,902,800
-16.4%
10,420,000
+15.1%
1.29%
-17.1%
BuyNUVALENT INC$49,281,088
+6.4%
1,888,888
+21.4%
0.73%
+5.6%
RNA BuyAVIDITY BIOSCIENCES INC$38,528,500
-15.3%
2,510,000
+22.4%
0.57%
-16.0%
DSGN BuyDESIGN THERAPEUTICS INC$20,195,000
-13.4%
3,500,000
+54.0%
0.30%
-14.1%
VRCA NewVERRICA PHARMACEUTICALS INC$17,225,000–2,650,000
+100.0%
0.26%–
MCRB NewSERES THERAPEUTICS INC$7,342,650–1,295,000
+100.0%
0.11%–
SRPT NewSAREPTA THERAPEUTICS INCcall$3,675,000–250,000
+100.0%
0.05%–
ISEE NewIVERIC BIO INCcall$1,837,500–875,000
+100.0%
0.03%–
XBI NewSPDR SERIES TRUST - S&P BIOTECHcall$180,000–1,500,000
+100.0%
0.00%–
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
AMICUS THERAPEUTICS INC36Q3 202317.9%
MIRATI THERAPEUTICS INC.35Q3 202317.2%
BIOMARIN PHARMACEUTICAL INC31Q3 20238.0%
SAREPTA THERAPUTICS INC28Q3 202314.8%
ASCENDIS PHARMA28Q3 20239.1%
ARGENX SE26Q3 20239.5%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%
FENNEC PHARMACEUTICALS INC25Q3 20230.4%
MADRIGAL PHARMACEUTICALS INC22Q3 20237.2%
XENON PHARMACEUTICALS INC22Q3 20233.3%

View Avoro Capital Advisors LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Avoro Capital Advisors LLC Q1 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Adverum Biotechnologies, Inc.Sold outFebruary 14, 202300.0%
DICE Therapeutics, Inc.February 14, 20232,525,5555.3%
IOVANCE BIOTHERAPEUTICS, INC.February 14, 20237,020,0004.4%
IVERIC bio, Inc.February 14, 20236,750,0005.0%
Kura Oncology, Inc.February 14, 20233,105,0004.5%
Aadi Bioscience, Inc.September 26, 20222,849,40211.7%
ARENA PHARMACEUTICALS INCFebruary 11, 20221,235,0002.0%
AVADEL PHARMACEUTICALS PLCFebruary 11, 20221,670,0002.9%
FENNEC PHARMACEUTICALS INC.February 11, 20221,200,0004.6%
POINT Biopharma Global Inc.Sold outFebruary 11, 202200.0%

View Avoro Capital Advisors LLC's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G/A2024-04-23
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Avoro Capital Advisors LLC's complete filings history.

All filings

View complete filings history.

Compare quarters

Export Avoro Capital Advisors LLC's holdings

CSVXLS